Subjective well-being of patients with schizophrenia as a target of drug treatment

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1490-1499

  Karamatskos, E ^a   Mulert, C ^a   Lambert, M ^a   Naber, D ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antipsychotic agents; Reward system; Schizophrenia; Subjective well being

Indexed keywords

AMISULPRIDE; CLOZAPINE; DOPAMINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZOTEPINE;

ANHEDONIA; APATHY; ARTICLE; CLINICAL ASSESSMENT; COGNITION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSPHORIA; EMOTION; HUMAN; INTEGRATION; LIFE SATISFACTION; MARRIAGE; NEUROIMAGING; PHYSICAL ACTIVITY; PLEASURE; QUALITY OF LIFE; REWARD; SCHIZOPHRENIA; SELF CARE; SELF CONTROL; SELF EVALUATION; SELF REPORT; SHORT FORM 36; SOCIAL STATUS; SOCIAL SUPPORT; STRESS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WELLBEING;

DOPAMINE; HUMANS; PERCEPTION; QUALITY OF LIFE; REWARD; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84862624182     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784862     Document Type: Article

References (104)

1. de Millas, W.; Lambert, M.; Naber, D. The impact of subjective well-being under neuroleptic treatment on compliance and remission. Dialogues Clin. Neurosci., 2006, 8, 131-136.
2. Baldessarini, R.J.; Tarsy, D. Pathophysiologic basis of tardive dyskinesia. Adv. Biochem. Psychopharmacol., 1980, 24, 451-455.
3. Tarsy, D. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin. Neuropharmacol., 1983, (6 Suppl. 1), S9-26.
4. Lewander, T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta. Psychiatr. Scand. Suppl., 1994, 380, 8-13.
5. Modestin, J.; Stephan, P.L.; Erni, T.; Umari, T. Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr., Res., 2000, 42, 223-230.
6. Hoiberg, M.P.; Nielsen, B. Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients. Nord J. Psychiatry, 2006, 60, 207-212.
7. Casey, D.E. Motor and mental aspects of extrapyramidal syndromes. Int. Clin. Psychopharmacol., 1995, (10 Suppl. 3), 105-114.
8. Browne, S.; Garavan, J.; Gervin, M.; Roe, M.; Larkin, C.; O'Callaghan, E. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J. Nerv. Ment. Dis., 1998, 186, 74-78.
9. Van Putten, T.; May, R.P. Akinetic depression in schizophrenia. Arch. Gen. Psychiatry, 1978, 35, 1101-1107.
10. Lader, M. Neuroleptic-induced deficit syndrome. Historical introduction. Acta. Psychiatr. Scand. Suppl., 1994, 380, 6-7.
11. Van Putten, T.; Marder, S.R. Behavioral toxicity of antipsychotic drugs. J. Clin. Psychiatry, 1987, 48(Suppl.), 13-19.
12. Carpenter, W.T. Jr.; Heinrichs, D.W.; Wagman, A.M. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry, 1988, 145, 578-583.
13. Windgassen, K. Treatment with neuroleptics: the patient's perspective. Acta. Psychiatr. Scand., 1992, 86, 405-410.
14. Collins, E.J.; Hogan, T.P.; Desai, H. Measurement of therapeutic response in schizophrenia. A critical survey. Schizophr. Res., 1991, 5, 249-253.
15. Naber, D.; Moritz, S.; Lambert, M.; Pajionk, F.G.; Holzbach, R.; Mass, R.; Andresen, B. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res., 2001, 50, 79-88.
16. Voruganti, L.; Heslegrave, R.; Awad, A.G.; Seeman, M.V. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol. Med., 1998, 28, 165-172.
17. Revicki, D.A.; Genduso, L.A.; Hamilton, S.H.; Ganoczy, D.; Beasley, C.M. Jr. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual. Life Res. 1999, 8, 417-426.
18. Tunis, S.L.; Croghan, T.W.; Heilman, D.K.; Johnstone, B.M.; Obenchain, R.L. Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Med. Care, 1999, 37, 678-691.
19. Voruganti, L.; Cortese, L.; Oyewumi, L.; Cernovsky, Z.; Zirul, S.; Awad, A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr. Res., 2000, 43, 135-145.
20. Van Putten, T.; May, P.R. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch. Gen Psychiatry, 1978, 35, 477-480.
21. Van Putten, T.; May, P.R.; Marder, S.R.; Wittmann, L.A. Subjective response to antipsychotic drugs. Arch. Gen Psychiatry, 1981, 38, 187-190.
22. Golubovic, B.; Misic-Pavkov, G.; Gajic, Z.; Ivanovic-Kovacevic, S. Evaluation of quality of life for patients with schizophrenic and schizoaffective disorders related to the use of antipsychotic therapy. Med. Arh., 2010, 64, 37-40.
23. Andreasen, N.C.; Carpenter, W.T. Jr.; Kane, J.M.; Lasser, R.A.; Marder, S.R.; Weinberger, D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry, 2005, 162, 441-449.
24. Lambert, M.; Schimmelmann, B.G.; Naber, D.; Schacht, A.; Karow, A.; Wagner, T.; Czekalla, J. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J. Clin. Psychiatry, 2006, 67, 1690-1697.
25. Lambert, M.; Naber, D.; Eich, F.X.; Schacht, M.; Linden, M.; Schimmelmann, B.G. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta. Psychiatr. Scand. 2007, 115, 106-113.
26. Lambert, M.; Naber, D.; Schacht, A.; Wagner, T.; Hundemer, H.P.; Karow, A.; Huber, C.G.; Suarez, D.; Haro, J.M.; Novick, D.; Dittmann, R.W.; Schimmelmann, B.G. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta. Psychiatr. Scand. 2008, 118, 220-229.
27. Lambert, M.; Schimmelmann, B.G.; Schacht, A.; Karow, A.; Wagner, T.; Wehmeier, P.M.; Huber, C.G.; Hundemer, H.P.; Dittmann, R.W.; Naber, D. Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years. Schizophr. Res., 2009, 107, 165-172.
28. Karow, A.; Czekalla, J.; Dittmann, R.W.; Schacht, A.; Wagner, T.; Lambert, M.; Schimmelmann, B.G.; Naber, D. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J. Clin. Psychiatry, 2007, 68, 75-80.
29. Wehmeier, P.M.; Kluge, M.; Schacht, A.; Helsberg, K.; Schreiber, W. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr. Res., 2007, 91, 178-186.
30. Wehmeier, P.M.; Kluge, M.; Schneider, E.; Schacht, A.; Wagner, T.; Schreiber, W. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 703-712.
31. Perkins, D.O.; Johnson, J.L.; Hamer, R.M.; Zipursky, R.B.; Keefe, R.S.; Centorrhino, F.; Green, A.I.; Glick, I.B.; Kahn, R.S.; Sharma, T.; Tohen, M.; McEvoy, J.P.; Weiden, P.J.; Lieberman, J.A.; HGDH Research Group. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr. Res., 2006, 83, 53-63.
32. de Haan, L.; Nimwegen, L.; Amelsvoort, T.; Dingemans, P.; Linszen, D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry, 2008, 41, 125-128.
33. Calman, K.C. Quality of life in cancer patients--an hypothesis. J. Med. Ethics, 1984, 10, 124-127.
34. Bullinger, M.; Hasford, J. Evaluating quality-of-life measures for clinical trials in Germany. Control Clin. Trials, 1991, 12, 91S-105S.
35. Awad, A.G.; Voruganti, L.N.; Heslegrave, R.J. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics, 1997, 11, 32-47.
36. Awad, A.G.; Hogan, T.P. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta. Psychiatr. Scand. Suppl. 1994, 380, 27-32.
37. Noll, R.L.; Hoencamp, E.; Nolen, W.A. Subjective side effects of neuroleptic agents. Ned. Tijdschr. Geneeskd., 1991, 135, 2113-2116.
38. Naber, D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int. Clin. Psychopharmacol., 1995, 10 (Suppl. 3), 133-138.
39. de Haan, L.; van Raaij, B.; van den Berg, R.; Jager, M.; Houweling, P.; Stockmann, M.; Delsing, P.; Linszen, D.; Peters, B.; Wouters, L. Preferences for treatment during a first psychotic episode. Eur. Psychiatry, 2001, 16, 83-89.
40. Schimmelmann, B.G.; Schacht, M.; Perro, C.; Lambert, M. [The initial dysphoric reaction (IDR) to the first dose of neuroleptics]. Nervenarzt, 2004, 75, 36-43.
41. Lambert, M.; Schimmelmann, B.G.; Karow, A.; Naber, D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance. Pharmacopsychiatry, 2003, 36 (Suppl. 3), S181-190.
42. Ramaekers, J.G.; Louwerens, J.W.; Muntjewerff, N.D.; Milius, H.; de Bie, A.; Rosenzweig, P.; Patat, A.; O'Hanlon, J.F. Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J. Clin. Psychopharmacol., 1999, 19, 209-221.
43. Meltzer, H.Y.; Burnett, S.; Bastani, B.; Ramirez, L.F. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp. Community Psychiatry, 1990, 41, 892-897.
44. Skantze, K.; Malm, U.; Dencker, S.J.; May, P.R.; Corrigan, P. Comparison of quality of life with standard of living in schizophrenic out-patients. Br. J. Psychiatry, 1992, 161, 797-801.
45. Carpiniello, B.; Lai, G.L.; Pariante, C.M.; Carta, M.G.; Rudas, N. Symptoms, standards of living and subjective quality of life: a comparative study of schizophrenic and depressed out-patients. Acta. Psychiatr. Scand., 1997, 96, 235-241.
46. Sainfort, F.; Becker, M.; Diamond, R. Judgments of quality of life of individuals with severe mental disorders: Patient self-report versus provider perspectives. Am. J. Psychiatry, 1996, 153, 497-502.
47. Atkinson, M.; Zibin, S.; Chuang, H. Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am. J. Psychiatry, 1997, 154, 99-105.
48. McGlashan, T.H. The Chestnut Lodge follow-up study. II. Longterm outcome of schizophrenia and the affective disorders. Arch. Gen Psychiatry, 1984, 41, 586-601.
49. Franz, M.; Meyer, T.; Reber, T.; Gallhofer, B. The importance of social comparisons for high levels of subjective quality of life in chronic schizophrenic patients. Qual. Life Res., 2000, 9, 481-489.
50. Bullinger, M. Generic quality of life assessment in psychiatry. Potentials and limitations. Eur. Psychiatry, 1997, 12, 203-209.
51. Awad, A.G.; Voruganti, L.N.; Heslegrave, R.J. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual. Life Res., 1994, 6, 21-26.
52. Gill, T.M.; Feinstein, A.R. A critical appraisal of the quality of quality-of-life measurements. JAMA, 1994, 272, 619-626.
53. de Haan, L.; Weisfelt, M.; Dingemans, P.M.; Linszen, D.H.; Wouters, L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology (Berl.), 2002, 162, 24-28.
54. Prieto, L.; Novick, D.; Sacristan, J.A.; Edgell, E.T.; Alonso, J. A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta. Psychiatr. Scand. Suppl., 2003, (416), 24-29.
55. Karow, A.; Moritz, S.; Lambert, M.; Schoder, S.; Krausz, M. PANSS syndromes and quality of life in schizophrenia. Psychopathology, 2005, 38, 320-326.
56. Essock, S.M.; Hargreaves, W.A.; Covell, N.H.; Goethe, J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull., 1996, 32, 683-697.
57. Rosenheck, R.; Cramer, J.; Xu, W.; Thomas, J.; Henderson, W.; Frisman, L.; Fye, C.; Charney, D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N. Engl. J. Med., 1997, 337, 809-815.
58. Tollefson, G.D.; Beasley, C.M. Jr.; Tamura, R.N.; Tran, P.V.; Potvin, J.H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. J. Psychiatry, 1997, 154, 1248-1254.
59. Hamilton, S.H.; Revicki, D.A.; Edgell, E.T.; Genduso, L.A.; Tollefson, G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics, 1999, 15, 469-480.
60. Hogan, T.P.; Awad, A.G.; Eastwood, R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med., 1983, 13, 177-183.
61. Bobes, J.; Gutiérrez, M.; Gibert, J.; Gonzalez, M.; Herraiz, L.; Fernández, A. Quality of life in schizophrenia: Long-term followup in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. Eur. Psychiatry, 1998, 13, 158-163.
62. Bobes, J.; Gutierrez, M.; Gibert, J.; Gonzalez, M.P.; Herraiz, M.L. [Quality of life and disability in chronic schizophrenics treated with with risperidone and previously treated with depot neuroleptics]. Actas. Esp. Psiquiatr., 1999, 27, 229-234.
63. Colonna, L.; Saleem, P.; Dondey-Nouvel, L.; Rein, W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int. Clin. Psychopharmacol., 2000, 15, 13-22.
64. Tollefson, G.D.; Andersen, S.W. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? J. Clin. Psychiatry, 1999, 60(Suppl. 5), 23-29; discussion 30.
65. Ho, B.C.; Miller, D.; Nopoulos, P.; Andreasen, N.C. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J. Clin. Psychiatry, 1999, 60, 658-663.
66. Franz, M.; Lis, S.; Pluddemann, K.; Gallhofer, B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br. J. Psychiatry, 1997, 170, 422-425.
67. Blum, K.; Chen, A.L.; Chen, T.J.; Braverman, E.R.; Reinking, J.; Blum, S.H.; Cassel, K.; Downs, B.W.; Waite, R.L.; Williams, L.; Prihoda, T.J.; Kerner, M.M.; Palomo, T.; Comings, D.E.; Tung, H.; Rhoades, P.; Oscar-Berman, M. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor. Biol. Med. Model, 2008, 5, 24.
68. Radwan, G.N.; El-Setouhy, M.; Mohamed, M.K.; Hamid, M.A.; Azem, S.A.; Kamel, O.; Israel, E.; Loffredo, C.A. DRD2/ANKK1 TaqI polymorphism and smoking behavior of Egyptian male cigarette smokers. Nicotine Tob. Res., 2007, 9, 1325-1329.
69. Xu, K.; Lichtermann, D.; Lipsky, R.H.; Franke, P.; Liu, X.; Hu, Y.; Cao, L.; Schwab, S.G.; Wildenauer, D.B.; Bau, C.H.; Ferro, E.; Astor, W.; Finch, T.; Terry, J.; Taubman, J.; Maier, W.; Goldman, D. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. Arch. Gen Psychiatry, 2004, 61, 597-606.
70. Volkow, N.D.; Fowler, J.S.; Wang, G.J.; Goldstein, R.Z. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol. Learn Mem., 2002, 78, 610-624.
71. Koob, G.F.; Le Moal, M. Addiction and the brain antireward system. Annu. Rev. Psychol., 2008, 59, 29-53.
72. Akhondzadeh, S. The 5-HT hypothesis of schizophrenia. IDrugs, 2001, 4, 295-300.
73. Glick, I.D.; Lemmens, P.; Vester-Blokland, E. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. Int. Clin. Psychopharmacol., 2001, 16, 265-274.
74. Andreasen, N.C. Positive and negative symptoms: historical and conceptual aspects. Mod. Probl. Pharmacopsychiatry, 1990, 24, 1-42.
75. Kapur, S.; Barsoum, S.C.; Seeman, P. Dopamine D(2) receptor blockade by haloperidol. (3)H-raclopride reveals much higher occupancy than EEDQ. Neuropsychopharmacology, 2000, 23, 595-598.
76. de Haan, L.; Lavalaye, J.; van Bruggen, M.; van Nimwegen, L.; Booij, J.; van Amelsvoort, T.; Linszen, D. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can. J. Psychiatry, 2004, 49, 290-296.
77. Arnt, J. Pharmacological differentiation of classical and novel antipsychotics. Int. Clin. Psychopharmacol., 1998, (13 Suppl. 3), S7-14.
78. Lyness, W.H.; Friedle, N.M.; Moore, K.E. Destruction of dopaminergic nerve terminals in nucleus accumbens: effect on damphetamine self-administration. Pharmacol. Biochem. Behav., 1979, 11, 553-556.
79. Roberts, D.C.; Corcoran, M.E.; Fibiger, H.C. On the role of ascending catecholaminergic systems in intravenous selfadministration of cocaine. Pharmacol. Biochem. Behav., 1977, 6, 615-620.
80. Wise, R.A.; Spindler, J.; deWit, H.; Gerberg, G.J. Neurolepticinduced anhedonia in rats: pimozide blocks reward quality of food. Science, 1978, 201, 262-264.
81. Voruganti, L.; Awad, A.G. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl.), 2004, 171, 121-132.
82. Heinz, A.; Knable, M.B.; Coppola, R.; Gorey, J.G.; Jones, D.W.; Lee, K.S.; Weinberger, D.R. Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. Schizophr. Res., 1998, 31, 19-26.
83. Honey, G.D.; Bullmore, E.T.; Soni, W.; Varatheesan, M.; Williams, S.C.; Sharma, T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Natl. Acad. Sci. U S A, 1999, 96, 13432-13437.
84. Bertolino, A.; Caforio, G.; Blasi, G.; De Candia, M.; Latorre, V.; Petruzzella, V.; Altamura, M.; Nappi, G.; Papa, S.; Callicott, J.H.; Mattay, V.S.; Bellomo, A.; Scarabino, T.; Weinberger, D.R.; Nardini, M. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry, 2004, 161, 1798-1805.
85. Goldstein, R.Z.; Volkow, N.D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry, 2002, 159, 1642-1652.
86. Crespo-Facorro, B.; Paradiso, S.; Andreasen, N.C.; O'Leary, D.S.; Watkins, G.L.; Ponto, L.L.; Hichwa, R.D. Neural mechanisms of anhedonia in schizophrenia: a PET study of response to unpleasant and pleasant odors. JAMA, 2001, 286, 427-435.
87. Juckel, G.; Schlagenhauf, F.; Koslowski, M.; Wüstenberg, T.; Villringer, A.; Knutson, B.; Wrase, J.; Heinz, A. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage, 2006, 29, 409-416.
88. Kapur, S.; Seeman, P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry, 2001, 158, 360-369.
89. Juckel, G.; Schlagenhauf, F.; Koslowski, M.; Filonov, D.; Wüstenberg, T.; Villringer, A.; Knutson, B.; Kienast, T.; Gallinat, J.; Wrase, J.; Heinz, A. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl.), 2006, 187, 222-228.
90. Farde, L.; Nordström, A.L.; Wiesel, F.A.; Pauli, S.; Halldin, C.; Sedvall, G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry, 1992, 49, 538-544.
91. Sawa, A.; Snyder, S.H. Schizophrenia: neural mechanisms for novel therapies. Mol. Med., 2003, 9, 3-9.
92. Corlett, P.R.; Murray, G.K.; Honey, G.D.; Aitken, M.R.; Shanks, D.R.; Robbins, T.W.; Bullmore, E.T.; Dickinson, A.; Fletcher, P.C. Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. Brain, 2007, 130, 2387-2400.
93. Jensen, J.; Willeit, M.; Zipursky, R.B.; Savina, I.; Smith, A.J.; Menon, M.; Crawley, A.P.; Kapur, S. The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology, 2008, 33, 473-479.
94. Murray, G.K.; Corlett, P.R.; Clark, L.; Pessiglione, M.; Blackwell, A.D.; Honey, G.; Jones, P.B.; Bullmore, E.T.; Robbins, T.W.; Fletcher, P.C. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol. Psychiatry, 2008, 13, 239, 267-276.
95. Mizrahi, R.; Rusjan, P.; Agid, O.; Graff, A.; Mamo, D.C.; Zipursky, R.B.; Kapur, S. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am. J. Psychiatry, 2007, 164, 630-637.
96. Schlagenhauf, F.; Juckel, G.; Kosloeski, M.; Kahnt, T.; Knutson, B.; Dembler, T.; Kienast, T.; Gallinat, J.; Wrase, J.; Heinz, A. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl.), 2008, 196, 673-684.
97. Meltzer, H.Y.; Li, Z.; Kaneda, Y.; Ichikawa, J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27, 1159-1172.
98. Lisman, J.E.; Coyle, J.T.; Green, R.W.; Javitt, D.C.; Benes, F.M.; Heckers, S.; Grace, A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends. Neurosci., 2008, 31, 234-242.
99. Mulert, C.; Leicht, G.; Hepp, P.; Kirsch, V.; Karch, S.; Pogarell, O.; Reiser, M.; Hegerl, U.; Jäger, L.; Moller, H.J.; McCarley, R.W. Single-trial coupling of the gamma-band response and the corresponding BOLD signal. Neuroimage, 2010, 49, 2238-2247.
100. Schlagenhauf, F.; Dinges, M.; Beck, A.; Wüstenberg, T.; Friedel, E.; Dembler, T.; Sarkar, R.; Wrase, J.; Gallinat, J.; Juckel, G.; Heinz, A. Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation. Schizophr. Res., 2010, 118, 189-200.
101. Gray, L.; van den Buuse, M.; Scarr, E.; Dean, B.; Hannan, A.J. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int. J. Neuropsychopharmacol., 2009, 12, 45-60.
102. Burt, T.; Lisanby, S.H.; Sackeim, H.A. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int. J. Neuropsychopharmacol., 2002, 5, 73-103.
103. Freitas, C.; Fregni, F.; Pascual-Leone, A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr. Res., 2009, 108, 11-24.
104. Fleischhacker, W.W.; Cetkovich-Bakmas, M.; De Hert, M.; Hennekens, C.H.; Lambert, M.; Leucht, S.; Maj, M.; McIntyre, R.S.; Naber, D.; Newcomer, J.W.; Olfson, M.; Osby, U.; Sartorius, N.; Lieberman, J.A. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J. Clin. Psychiatry, 2008, 69, 514-519.